Medical and Cellular Therapies in Hair Loss Treatment

ISHRS 2025 CME Webinar

Medical and Cellular Therapies in Hair Loss Treatment

Wednesday, April 16, 2025
12:00PM-2:30PM CDT
12:00PM Central Time (Time Zone Conversion)
Duration: 2 hours 30 minutes

Registration Fees Per Webinar

Moderators

Moderator: Ratchathorn Panchaprateep, MD, PhD, FISHRS | Thailand
Co-Moderator: Anil K. Garg, MBBS, MS, MCh, FISHRS | India

Program Description

This 2.5-hour live webinar, “Medical and Cellular Therapies in Hair Loss Treatment,” will cover a range of advanced medical and cellular therapies for the treatment of hair loss, including low-dose oral and sublingual minoxidil, intralesional treatments for androgenetic alopecia (AGA), new treatments for scarring alopecia, lasers in hair loss treatment, cell-based therapies, cell-free therapies, advanced PRP techniques, and discussions on hair follicle stem cells. The webinar will provide a comprehensive overview of FDA-approved treatments, hormonal therapies, stem cell therapy, PRP protocols, emerging molecules, and the integration of medical and surgical treatments for hair loss.

Professional Practice Gap

Many healthcare professionals may not be aware of the latest advancements in medical and cellular therapies for hair loss. There is a gap in knowledge and understanding of the efficacy, safety, and appropriate use of these treatments in clinical practice. This webinar aims to bridge this gap by providing up-to-date information on advanced therapies for hair loss.

Educational Need

Healthcare professionals need to stay informed about the latest developments in hair loss treatment to provide optimal care for patients. With the increasing demand for effective and innovative treatments for hair loss, it is essential for professionals to have a comprehensive understanding of medical and cellular therapies. This webinar will address the educational need for updated knowledge and skills in this evolving field.

Learning Objectives

By the end of this webinar, participants will be able to:

1. Describe the FDA-approved medical treatments for hair loss and their mechanisms of action.
2. Evaluate the role of hormonal therapies in managing hair loss conditions.
3. Examine the potential of stem cell therapy and cellular therapies in hair restoration.
4. Discuss the concept of hair cloning and follicle regeneration in treating hair loss.
5. Compare different protocols and approaches for PRP therapy in hair loss treatment.
6. Identify emerging molecules for hair loss and their potential applications.
7. Integrate medical and surgical treatments for a comprehensive approach to hair loss management.
8. Explain the importance of nutritional and supplementary support in promoting hair growth and health.

Target Audience and Prerequisites

This webinar is taught at the physician level. It is open to all levels and geared toward advanced hair restoration surgeons.

References

1. TBA

CME Information

Continuing Medical Education (CME) Credit Statement

The International Society of Hair Restoration Surgery is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Society of Hair Restoration Surgery designates this Other Activity (blended synchronous and enduring) for a maximum of 2.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive CME credit and a CME certificate, participants must participate in the activity, complete the evaluation survey and the CME Claim Form by January 12, 2026.

Format

Internet/online, via computer or mobile device. 

Official Language

The official language of the webinar is English. Simultaneous interpretation is not provided for this webinar.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the ISHRS must ensure that anyone in a position to control the content of the educational activity (planners/ speakers/authors/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

• Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
• Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.  ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
• Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ISHRS manage any reported conflict and eliminate the potential for bias during the educational activity.  Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Disclosures of Relevant Financial Relationships of Planners, Faculty, and Others

The following individuals have no relevant financial relationships with ineligible companies to disclose:

Planners

Marco Barusco, MD, FISHRS – Planner
Victoria Ceh, MPA – Planner & Manager
Anil K. Garg, MBBS, MS, MCh, FISHRS – Planner, Moderator & Faculty
Aditya K. Gupta, MD, PhD, FISHRS – Planner
Robert S. Haber, MD, FISHRS – Planner
Rana Irfan, MBBS, FISHRS – Planner
Marissa LaDue, MPH – Planner & Manager
Hafiz Waqar Maqsood, MBBS – Planner
Maira Merlotto, MD, MsC – Planner
Ratchathorn Panchaprateep, MD, PhD, FISHRS – Planner, Moderator & Faculty
Farhaad Riyaz, MD – Planner
Nicole E. Rogers, MD, FISHRS – Planner
Marie A. Schambach, MD, FISHRS – Planner
Miriam Scheel, MD – Planner
Melanie Stancampiano – Planner & Manager

Faculty

Andrei Doroshkevich, MD
Anil K. Garg, MBBS, MS, MCh, FISHRS
Seema Garg, MBBS, MSc, FISHRS
Paulo Muller Ramos, MD
Ratchathorn Panchaprateep, MD, PhD, FISHRS
Nicole E. Rogers, MD, FISHR
Maryanne Senna, MD
Sergio Vañó Galván, MD, PhD

The following individuals have relevant financial relationships:

Planners

None

Faculty

Maryanne Senna, MD has served in the following roles within the past 24 months:

• Consultant, advisor, and/or speaker: Lilly, Pfizer, AbbVie, Inmagene, SUN Pharma
• Investigator: Leo Pharma, AbbVie, Inmagene

Sergio Vañó Galván, MD, PhD has served in the following roles within the past 24 months:

• Speaker and/or advisor: Almirall, Pfizer, Lilly, Novartis, Janssen, Cantabria Labs, Isdin, GSK, MSD, Pierre Fabre, Galderma, L’Oréal, Daniel Alain, AbbVie, Fotofinder, Skymedic
• Research funding: Novartis, Cantabria Labs, Fagron, DS

All of the relevant financial relationships listed for these individuals have been mitigated.

Commercial Support

None

Off-Label Or Other Non-FDA Approved, Investigational Use

Andrei Doroshkevich, MD has disclosed the following information:

• Presentation includes discussion of off-label or investigational use of a medical product: Dutasteride (Avodart, GlaxoSmithKline)

Paulo Muller Ramos, MD has disclosed the following information:

• Presentation includes discussion of off-label or investigational use of a medical product: Oral minoxidil (Pfizer)

Maryanne Senna, MD has disclosed the following information:

• Presentation includes discussion of off-label or investigational use of medical products: Topical and oral Janus kinase (JAK) inhibitors

Sergio Vañó Galván, MD, PhD has disclosed the following information:

• Presentation includes discussion of off-label or investigational use of a medical product: Bicalutamide

Other CME Information

Click for Continuing Medical Education Mission Statement
Learner Bill of Rights
ISHRS Privacy and Confidentiality Policy for Internet CME

Disclaimer

The webinar content has been made available by the ISHRS for educational purposes only. The content is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather is intended to present views, statements, and opinions that may be of interest to others. The views expressed herein are those of the individual authors and not necessarily those of the ISHRS. The ISHRS assumes no responsibility or liability in connection with your use or misuse of the webinar content or any materials or techniques described in the content, and it makes no warranty or representation as to the validity or sufficiency of any information provided.

Questions: Learners may contact the ISHRS Headquarters with questions about this CME activity at phone +1-800-444-2737 or +1-630-262-5399, or fax +1-630-262-1520, or email: gro.srhsiobfsctd-4e8c2d@ofni